Articles by David K. Blough, PhD

Colony-Stimulating Factor Prescribing Patterns in Patients Receiving Chemotherapy for Cancer
ByScott D. Ramsey, MD, PhD,Jeannine S. McCune, PharmD,David K. Blough, PhD,Cara L. McDermott, BA,Lauren Clarke, MS,Jennifer L. Malin, MD, PhD,Sean D. Sullivan, PhD We linked health insurance records to cancer registry data to analyze colony-stimulating factor use, finding wide divergence from that recommended by practice guidelines.

Preliminary Treatment Considerations Among Men With Newly Diagnosed Prostate Cancer
BySteven B. Zeliadt, PhD, MPH,Carol M. Moinpour, PhD,David K. Blough, PhD,David F. Penson, MD, MPH,Ingrid J. Hall, PhD, MPH,Judith Lee Smith, PhD,Donatus U. Ekwueme, PhD,Ian M. Thompson, MD,Thomas E. Keane, MB, ChB, FRCSI,Scott D. Ramsey, MD, PhD In a survey of local-stage prostate cancer patients, preference for prostatectomy was influenced by perceptions of its efficacy and personal burden versus nonsurgical options.

Increasing Copayments and Adherence to Diabetes, Hypertension, and Hyperlipidemic Medications
ByMatthew L. Maciejewski, PhD,Chris L. Bryson, MD, MS,Mark Perkins, PharmD,David K. Blough, PhD,Francesca E. Cunningham, PhD,John C. Fortney, PhD,Sarah L. Krein, PhD,Kevin T. Stroupe, PhD,Nancy D. Sharp, PhD,Chuan-Fen Liu, PhD A copayment increase from $2 to $7 adversely affected veterans' adherence to statins, antihypertensives, and oral hypoglycemic agents.

Second-line and Third-line Chemotherapy for Lung Cancer: Use and Cost
ByScott D. Ramsey, MD, PhD,Renato G. Martins, MD,David K. Blough, PhD,Lauri S. Tock, MHA,Deborah Lubeck, PhD,Carolina M. Reyes, PhD Using health insurance claims, we identified common first-, second-, and third-line chemotherapy regimens for patients with lung cancer and associated utilization and costs of care.